MAPT and chronic kidney disease: While blood-biomarker performance in real-world populations is generally quite favourable,38 the influence of systemic medical conditions such as chronic kidney disease,39 which was not accounted for in the current report, needs to be further elucidated; recent evidence suggests that plasma p-tau217/tau ratios may help in these cases.40